Immuno-Oncology | Specialty

PACIFIC Trial: Durvalumab for Stage 3 NSCLC

September 28th 2017

Immunotherapy for Management of Stage 3B NSCLC

September 28th 2017

Immunotherapy Toxicity Management in NSCLC

September 28th 2017

Treatment for NSCLC After Progression on Immunotherapy

September 28th 2017

Combination Approaches for Second-Line Therapy for NSCLC

September 28th 2017

The Role of Mutation Burden as a Biomarker in NSCLC

September 28th 2017

Immunotherapy for Relapsed or Refractory NSCLC

September 28th 2017

Isolated Progression of NSCLC on Immunotherapy

September 28th 2017

The Potential for IO Use as Maintenance Therapy in NSCLC

September 28th 2017

Duration of Upfront Immunotherapy for NSCLC

September 28th 2017

Patient Selection for Upfront Immunotherapy in NSCLC

September 28th 2017

Upfront PD-L1 Blockade in Newly Diagnosed NSCLC

September 28th 2017

NSCLC Immunotherapy: Transformation of Upfront Therapy

September 28th 2017

Bladder Cancer Paradigm Expanding to Include Immunotherapy Combos, Targeted Therapies

September 28th 2017

Terence Friedlander, MD, discusses the targeted therapies emerging in the field of bladder cancer, as well as immunotherapy combinations that are traveling through the pipeline.

Avelumab Approved in Japan for Merkel Cell Carcinoma

September 27th 2017

The Japanese Ministry of Health, Labor and Welfare has approved avelumab (Bavencio) for use in patients with metastatic Merkel cell carcinoma, according to Merck KGaA.

Pal Provides Key ESMO Updates in GU Malignancies

September 26th 2017

Sumanta Kumar Pal, MD, discusses the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Relatlimab/Nivolumab Combo Active in Melanoma After PD-1/PD-L1 Therapy

September 26th 2017

Half of patients with melanoma who progressed on anti-PD-1/PD-L1 therapy benefited from the combination of nivolumab and the LAG-3 inhibitor relatlimab.

Longer Follow-Up Shows Survival Increase With Rocapuldencel-T in mRCC

September 26th 2017

Patients with metastatic renal cell carcinoma appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells.

Dr. Larson on Immunotherapy for Colorectal Cancer

September 26th 2017

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Atezolizumab Approved in Europe for Lung, Bladder Cancer

September 25th 2017

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.